Contact Information: Contact Information: Stephen Feldschuh Chief Operating Officer 212-330-8515 or Diane Meegan Investor Relations 212-330-8512
Daxor Announces Virginia Commonwealth University Medical Center of Richmond, VA Acquires Blood Volume Analyzer BVA-100
| Source: Daxor Corp.
NEW YORK, NY--(Marketwire - October 1, 2007) - Daxor Corporation (AMEX : DXR ), a medical
instrumentation and biotechnology company, today announced the receipt of a
signed clinical trial agreement for a Blood Volume Analyzer BVA-100 from
Virginia Commonwealth University Medical Center of Richmond, Virginia.
Virginia Commonwealth University (VCU) Medical Center is a fully accredited
Level I trauma center and teaching medical center serving Central Virginia.
VCU Medical Center is ranked as one of the nation's Best Hospitals in 2007
by U.S. News & World Report and has also been recognized by The American
Nurses Credentialing Center, which awarded Virginia Commonwealth University
Health System Magnet status, the highest honor and level of recognition the
group awards to nursing excellence in national and international health
care. VCU Medical Center is fully accredited in cardiac and aortic
surgical procedures and is recognized as offering the region's most honored
open-heart surgery program. VCU Medical Center is also one of the nations
leading institutions in the field of blood conservation.
The national average for transfusion of blood in cardiac surgical patients
has been reported in various published clinical studies to be as high as
60%. At VCU, the transfusion rate is less than 20%. Transfusion of blood
for heart surgery accounts for about 20% of all the blood used in the
United Sates and up to 34% in parts of Europe. The latest data are sobering
showing that patients who receive more blood transfusions have worse
outcomes, more heart attacks, more heart failure, longer times in the
hospital, longer times on ventilators, more infections and twice the death
rate, even out to five years after heart surgery. Daxor's BVA-100 will be
used in cardiac surgery patients to measure their blood volume status prior
to and post cardiac surgery.
Dr. Mark Nelson, the study's principle investigator noted, "Transfusion of
blood is not as benign as was once assumed. This technology will allow us
to examine the patient's true blood volume and, along with other
information, determine in which patients' transfusion is truly necessary.
We expect the data we collect to profoundly impact the current national
transfusion practices in cardiac surgical patients." Following the
installation of the BVA-100 physicians will begin collecting data on blood
volumes in cardiac surgical patients and hope to publish their preliminary
findings later this year.
Daxor Corporation manufactures and markets the BVA-100, the only
FDA-approved semi-automated Blood Volume Analyzer. The BVA-100 is used in
conjunction with Volumex, Daxor's single use diagnostic kit. For more
information regarding Daxor Corporation's Blood Volume Analyzer BVA-100,
visit Daxor's website www.Daxor.com.